4.5 Article

Lessons Learned From Five Years of Newborn Screening for Severe Combined Immunodeficiency in Israel

Journal

Publisher

ELSEVIER
DOI: 10.1016/j.jaip.2022.04.013

Keywords

Severe combined immunodeficiency; SCID; T cell lymphopenia; Newborn screening; Dry blood spots; Primary immunodeficiency; Hematopoietic stem cell transplantation

Funding

  1. Israel Science Foundation under the Israel Precision Medicine Program [3115/19, 1505/18]

Ask authors/readers for more resources

This study provides a 5-year summary of the SCID newborn screening program in Israel, demonstrating its effectiveness and outcomes. The program achieved high specificity and sensitivity in detecting SCID cases, resulting in the diagnosis and management of 32 SCID infants. The study highlights the importance of implementing global SCID newborn screening programs and emphasizes the value of accumulating knowledge from screening data.
BACKGROUND: Implementation of newborn screening (NBS) programs for severe combined immunodeficiency (SCID) have advanced the diagnosis and management of affected infants and undoubtedly improved their outcomes. Reporting long-term follow-up of such programs is of great importance. OBJECTIVE: We report a 5-year summary of the NBS program for SCID in Israel. METHODS: Immunologic and genetic assessments, clinical analyses, and outcome data from all infants who screened positive were evaluated and summarized. RESULTS: A total of 937,953 Guthrie cards were screened for SCID. A second Guthrie card was requested on 1,169 occasions (0.12%), which resulted in 142 referrals (0.015%) for further validation tests. Flow cytometry immune-phenotyping, T cell receptor excision circle measurement in peripheral blood, and expression of TCRV beta repertoire for the validation of positive cases revealed a specificity and sensitivity of 93.7% and 75.9%, respectively, in detecting true cases of SCID. Altogether, 32 SCID and 110 non-SCID newborns were diagnosed, making the incidence of SCID in Israel as high as 1:29,000 births. The most common genetic defects in this group were associated with mutations in DNA cross-link repair protein 1C and IL-7 receptor a (IL-7R alpha) genes. No infant with SCID was missed during the study time. Twenty-two SCID patients underwent hematopoietic stem cell transplantation, which resulted in a 91% survival rate. CONCLUSIONS: Newborn screening for SCID should ultimately be applied globally, specifically to areas with high rates of consanguineous marriages. Accumulating data from follow-up studies on NBS for SCID will improve diagnosis and treatment and enrich our understanding of immune development in health and disease. (C) 2022 American Academy of Allergy, Asthma & Immunology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available